Cargando…

Simplifying prediction of disease progression in pre-symptomatic type 1 diabetes using a single blood sample

AIMS/HYPOTHESIS: Accurate prediction of disease progression in individuals with pre-symptomatic type 1 diabetes has potential to prevent ketoacidosis and accelerate development of disease-modifying therapies. Current tools for predicting risk require multiple blood samples taken during an OGTT. Our...

Descripción completa

Detalles Bibliográficos
Autores principales: Bediaga, Naiara G., Li-Wai-Suen, Connie S. N., Haller, Michael J., Gitelman, Stephen E., Evans-Molina, Carmella, Gottlieb, Peter A., Hippich, Markus, Ziegler, Anette-Gabriele, Lernmark, Ake, DiMeglio, Linda A., Wherrett, Diane K., Colman, Peter G., Harrison, Leonard C., Wentworth, John M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494707/
https://www.ncbi.nlm.nih.gov/pubmed/34338806
http://dx.doi.org/10.1007/s00125-021-05523-2
_version_ 1784579372917719040
author Bediaga, Naiara G.
Li-Wai-Suen, Connie S. N.
Haller, Michael J.
Gitelman, Stephen E.
Evans-Molina, Carmella
Gottlieb, Peter A.
Hippich, Markus
Ziegler, Anette-Gabriele
Lernmark, Ake
DiMeglio, Linda A.
Wherrett, Diane K.
Colman, Peter G.
Harrison, Leonard C.
Wentworth, John M.
author_facet Bediaga, Naiara G.
Li-Wai-Suen, Connie S. N.
Haller, Michael J.
Gitelman, Stephen E.
Evans-Molina, Carmella
Gottlieb, Peter A.
Hippich, Markus
Ziegler, Anette-Gabriele
Lernmark, Ake
DiMeglio, Linda A.
Wherrett, Diane K.
Colman, Peter G.
Harrison, Leonard C.
Wentworth, John M.
author_sort Bediaga, Naiara G.
collection PubMed
description AIMS/HYPOTHESIS: Accurate prediction of disease progression in individuals with pre-symptomatic type 1 diabetes has potential to prevent ketoacidosis and accelerate development of disease-modifying therapies. Current tools for predicting risk require multiple blood samples taken during an OGTT. Our aim was to develop and validate a simpler tool based on a single blood draw. METHODS: Models to predict disease progression using a single OGTT time point (0, 30, 60, 90 or 120 min) were developed using TrialNet data collected from relatives with type 1 diabetes and validated in independent populations at high genetic risk of type 1 diabetes (TrialNet, Diabetes Prevention Trial–Type 1, The Environmental Determinants of Diabetes in the Young [1]) and in a general population of Bavarian children who participated in Fr1da. RESULTS: Cox proportional hazards models combining plasma glucose, C-peptide, sex, age, BMI, HbA(1c) and insulinoma antigen-2 autoantibody status predicted disease progression in all populations. In TrialNet, the AUC for receiver operating characteristic curves for models named M(60), M(90) and M(120), based on sampling at 60, 90 and 120 min, was 0.760, 0.761 and 0.745, respectively. These were not significantly different from the AUC of 0.760 for the gold standard Diabetes Prevention Trial Risk Score, which requires five OGTT blood samples. In TEDDY, where only 120 min blood sampling had been performed, the M(120) AUC was 0.865. In Fr1da, the M(120) AUC of 0.742 was significantly greater than the M(60) AUC of 0.615. CONCLUSIONS/INTERPRETATION: Prediction models based on a single OGTT blood draw accurately predict disease progression from stage 1 or 2 to stage 3 type 1 diabetes. The operational simplicity of M(120), its validity across different at-risk populations and the requirement for 120 min sampling to stage type 1 diabetes suggest M(120) could be readily applied to decrease the cost and complexity of risk stratification. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version of this article (10.1007/s00125-021-05523-2) contains peer-reviewed but unedited supplementary material.
format Online
Article
Text
id pubmed-8494707
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-84947072021-10-19 Simplifying prediction of disease progression in pre-symptomatic type 1 diabetes using a single blood sample Bediaga, Naiara G. Li-Wai-Suen, Connie S. N. Haller, Michael J. Gitelman, Stephen E. Evans-Molina, Carmella Gottlieb, Peter A. Hippich, Markus Ziegler, Anette-Gabriele Lernmark, Ake DiMeglio, Linda A. Wherrett, Diane K. Colman, Peter G. Harrison, Leonard C. Wentworth, John M. Diabetologia Article AIMS/HYPOTHESIS: Accurate prediction of disease progression in individuals with pre-symptomatic type 1 diabetes has potential to prevent ketoacidosis and accelerate development of disease-modifying therapies. Current tools for predicting risk require multiple blood samples taken during an OGTT. Our aim was to develop and validate a simpler tool based on a single blood draw. METHODS: Models to predict disease progression using a single OGTT time point (0, 30, 60, 90 or 120 min) were developed using TrialNet data collected from relatives with type 1 diabetes and validated in independent populations at high genetic risk of type 1 diabetes (TrialNet, Diabetes Prevention Trial–Type 1, The Environmental Determinants of Diabetes in the Young [1]) and in a general population of Bavarian children who participated in Fr1da. RESULTS: Cox proportional hazards models combining plasma glucose, C-peptide, sex, age, BMI, HbA(1c) and insulinoma antigen-2 autoantibody status predicted disease progression in all populations. In TrialNet, the AUC for receiver operating characteristic curves for models named M(60), M(90) and M(120), based on sampling at 60, 90 and 120 min, was 0.760, 0.761 and 0.745, respectively. These were not significantly different from the AUC of 0.760 for the gold standard Diabetes Prevention Trial Risk Score, which requires five OGTT blood samples. In TEDDY, where only 120 min blood sampling had been performed, the M(120) AUC was 0.865. In Fr1da, the M(120) AUC of 0.742 was significantly greater than the M(60) AUC of 0.615. CONCLUSIONS/INTERPRETATION: Prediction models based on a single OGTT blood draw accurately predict disease progression from stage 1 or 2 to stage 3 type 1 diabetes. The operational simplicity of M(120), its validity across different at-risk populations and the requirement for 120 min sampling to stage type 1 diabetes suggest M(120) could be readily applied to decrease the cost and complexity of risk stratification. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version of this article (10.1007/s00125-021-05523-2) contains peer-reviewed but unedited supplementary material. Springer Berlin Heidelberg 2021-08-02 2021 /pmc/articles/PMC8494707/ /pubmed/34338806 http://dx.doi.org/10.1007/s00125-021-05523-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Bediaga, Naiara G.
Li-Wai-Suen, Connie S. N.
Haller, Michael J.
Gitelman, Stephen E.
Evans-Molina, Carmella
Gottlieb, Peter A.
Hippich, Markus
Ziegler, Anette-Gabriele
Lernmark, Ake
DiMeglio, Linda A.
Wherrett, Diane K.
Colman, Peter G.
Harrison, Leonard C.
Wentworth, John M.
Simplifying prediction of disease progression in pre-symptomatic type 1 diabetes using a single blood sample
title Simplifying prediction of disease progression in pre-symptomatic type 1 diabetes using a single blood sample
title_full Simplifying prediction of disease progression in pre-symptomatic type 1 diabetes using a single blood sample
title_fullStr Simplifying prediction of disease progression in pre-symptomatic type 1 diabetes using a single blood sample
title_full_unstemmed Simplifying prediction of disease progression in pre-symptomatic type 1 diabetes using a single blood sample
title_short Simplifying prediction of disease progression in pre-symptomatic type 1 diabetes using a single blood sample
title_sort simplifying prediction of disease progression in pre-symptomatic type 1 diabetes using a single blood sample
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494707/
https://www.ncbi.nlm.nih.gov/pubmed/34338806
http://dx.doi.org/10.1007/s00125-021-05523-2
work_keys_str_mv AT bediaganaiarag simplifyingpredictionofdiseaseprogressioninpresymptomatictype1diabetesusingasinglebloodsample
AT liwaisuenconniesn simplifyingpredictionofdiseaseprogressioninpresymptomatictype1diabetesusingasinglebloodsample
AT hallermichaelj simplifyingpredictionofdiseaseprogressioninpresymptomatictype1diabetesusingasinglebloodsample
AT gitelmanstephene simplifyingpredictionofdiseaseprogressioninpresymptomatictype1diabetesusingasinglebloodsample
AT evansmolinacarmella simplifyingpredictionofdiseaseprogressioninpresymptomatictype1diabetesusingasinglebloodsample
AT gottliebpetera simplifyingpredictionofdiseaseprogressioninpresymptomatictype1diabetesusingasinglebloodsample
AT hippichmarkus simplifyingpredictionofdiseaseprogressioninpresymptomatictype1diabetesusingasinglebloodsample
AT ziegleranettegabriele simplifyingpredictionofdiseaseprogressioninpresymptomatictype1diabetesusingasinglebloodsample
AT lernmarkake simplifyingpredictionofdiseaseprogressioninpresymptomatictype1diabetesusingasinglebloodsample
AT dimegliolindaa simplifyingpredictionofdiseaseprogressioninpresymptomatictype1diabetesusingasinglebloodsample
AT wherrettdianek simplifyingpredictionofdiseaseprogressioninpresymptomatictype1diabetesusingasinglebloodsample
AT colmanpeterg simplifyingpredictionofdiseaseprogressioninpresymptomatictype1diabetesusingasinglebloodsample
AT harrisonleonardc simplifyingpredictionofdiseaseprogressioninpresymptomatictype1diabetesusingasinglebloodsample
AT wentworthjohnm simplifyingpredictionofdiseaseprogressioninpresymptomatictype1diabetesusingasinglebloodsample